BR102375
Based on 1 publication(s) in Google Scholar
BR102375 is a non-TZD peroxisome proliferator-activated receptor γ (PPAR γ) full agonist for the treatment of type 2 diabetes, reveals EC50 value of 0.28 μM and Amax ratio of 98%.
For research use only. We do not sell to patients.
- CAS No.: 2366255-59-4
- Formula: C31H34N6O4
- Molecular Weight:554.64
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) BR102375
More
Biological Activity
Description
In Vitro
BR102375 (Compound 18) (10 μM) increases gene expression levels relevant to PPARγ activation and enhances glucose uptake under insulin stimulation[1]. BR102375 (Compound 18) (10 nM, 100 nM, 1 μM; 6 days, 14 days) shows a concentration-dependent, insulin-sensitive effects on adipogenesis[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:3T3-L1 mouse preadipocyte cells
-
Concentration:10 μM
-
Incubation Time:
-
Result:Increased AP2 and CD36 cells gene mRNA expression and enhanced glucose uptake when stimulated by insulin.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 2366255-59-4
-
Molecular Weight 554.64
-
Formula C31H34N6O4
-
SMILES
CCCCC(N1CC2=CC=C(C3=C(C4=NOC(N4)=O)C=CC=C3)C=C2)=NC(C)=C(CC5=NC(C(C)(C)C)=NO5)C1=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Life Sci
Protective role of long noncoding RNA CRNDE in myocardial tissues from injury caused by sepsis through the microRNA-29a/SIRT1 axis. [Abstract]2020 Aug 15:255:117849. PMID: 32473249
Protocols
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
Purity & Documentation
References
[1]. Choung W, et al. Discovery of BR102375, a new class of non-TZD PPARγ full agonist for the treatment of type 2 diabetes. Bioorg Med Chem Lett. 2019 Jun 19. pii: S0960-894X(19)30407-X. [Content Brief]
[2]. Yan Zhu, et al. Protective Role of Long Noncoding RNA CRNDE in Myocardial Tissues From Injury Caused by Sepsis Through the microRNA-29a/SIRT1 Axis. Life Sci. 2020 May 27;117849. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)